Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

• Results Overview

  Dupilumab significantly improved eczema symptoms, itching, anxiety, depression, and quality of life compared to placebo in adults with moderate-to-severe eczema over 16 weeks of treatment.

• Study Summary

  Num Participants:

  1,379

  Study Type:

  Rct

  Control Group:

  Placebo

  Efficacy End Points Treatment:

  {'IGA 0/1': 37, 'EASI-75': 36}

  Efficacy End Points Control:

  {'IGA 0/1': 9, 'EASI-75': 8}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Injection-Site Reactions	Low
  Conjunctivitis	Low

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected